Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Thoughts on how this slide changed over time?

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Nov 12, 2021 1:54pm

99 Views

Post# 34120724

RE:RE:Thoughts on how this slide changed over time?

I was doing a week calculation to using 28 weeks. I think one mistake that makes is that it doesn't account for the 2-4 weeks between patient enrollments that they have faced and that they stated at the quarterly conf call. So if you add in a few of these 2-4 week gaps, it's probably where we are.

I am also looking at slides 18 and 19 for the CS call. He states there are "several" patients now at the 420 level that they are "dosing now". I guess that means at least 1 more. It sounds like he's saying that if they hit some DLTs and do the 6 person final run now, it would end close to year end. If they're fine and go up one more level and then do the 6 person final run, it's likely January. So I would say either gives you a rather large dose.

I do have a question around the SAE issue. We've heard 2 things and I'm really not sure where it stands. First we heard there was a Grade 4 Neutropenia (non-febrile). From all I can find, that is still considered an SAE4 event. But Marsolais said it was Grade 4 Neutropenia but only a Grade 2 SAE. I just don't get that. Has anyone been able to get to the bottom of that? In this new presentation it seems like a Grade 4 SAE.

SPCEO - on images, best thing is to upload them to Imgur.com and they provide you the link. Copy the link and put it in these messages as a hyper link (that weird upward arrow sign above). Imgur is anonymous and deletes it after a while. Only way I've found that works.

SPCEO1 wrote: Oh well Stockhouse never seems to post an image I try to include. If any of you know the trick to allow an image to s how up, let me know. It shows up when I prepare the post but never shows up when the post is posted.

SPCEO1 wrote: The first one is from the 7/19/21 Corproate Presentation and the second from yesterday's presentation - (I am hoping Stockhouse will allow the two slides to show up in this post).

One question is how did the original estimate of 28 weeks for phase 1a get so off track? Especially when they were only dosing 5 patients to get to the level where the dosage exceeds the normal dosage of Docetaxel?